RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
P/E ratio for RxSight, Inc. (RXST)
P/E ratio as of 2023: -28.58
According to RxSight, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -28.58. At the end of 2022 the company had a P/E ratio of -5.25.
P/E ratio history for RxSight, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -28.58 |
| 2022 | -5.25 |
| 2021 | -6.32 |
| 2020 | 16.03 |
| 2019 | 3.50 |